Keith A. Kucinski - 15 Dec 2023 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role
Chief Financial Officer
Signature
/s/ Keith A. Kucinski
Issuer symbol
MTNB
Transactions as of
15 Dec 2023
Net transactions value
$0
Form type
4
Filing time
15 Dec 2023, 21:46:25 UTC
Previous filing
22 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Stock Option (right to Buy) Award $0 +1,000,000 $0.000000 1,000,000 15 Dec 2023 Common Stock 1,000,000 $0.2470 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.